arrow_back Trending Legislation
Share share

Faster Approval of Generic Drugs with New Safety Information

This act aims to accelerate the market entry of more affordable generic drugs. It allows for their approval even if certain safety information, protected by exclusivity for original drugs, is missing. This means citizens could gain quicker access to cheaper drug alternatives, potentially lowering healthcare costs.
Key points
Generic drugs can be approved faster, even if their labels omit safety information protected by exclusivity for original drugs.
Essential safety information will still be required on generic drug labels to ensure safe use.
The act does not affect existing exclusivity rights for original drugs but facilitates access to cheaper alternatives.
This could lead to lower drug costs for patients and increased availability of important treatments.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Prompt Approval of Safe Generic Drugs Act
Print number: HR 2831
Sponsor: Rep. Barragan, Nanette Diaz [D-CA-44]
Process start date: 2021-04-26
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Faster Approval of Generic Drugs with New Safety Information

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 2831.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-26.

What are the main provisions?

Key points include:

  • Generic drugs can be approved faster, even if their labels omit safety information protected by exclusivity for original drugs.
  • Essential safety information will still be required on generic drug labels to ensure safe use.
  • The act does not affect existing exclusivity rights for original drugs but facilitates access to cheaper alternatives.
  • This could lead to lower drug costs for patients and increased availability of important treatments.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Barragan, Nanette Diaz [D-CA-44].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Analysis and Potential Impact of HR 2831

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health